• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估免疫相关的eRNA模型和特征分数,以预测甲状腺癌对免疫治疗的反应。

Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma.

作者信息

Wu Pu, Shi Jinyuan, Wang Zhiyuan, Sun Wei, Zhang Hao

机构信息

Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China.

出版信息

Cancer Cell Int. 2022 Oct 10;22(1):307. doi: 10.1186/s12935-022-02722-8.

DOI:10.1186/s12935-022-02722-8
PMID:36217201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9549686/
Abstract

BACKGROUND

The functional alterations of eRNAs have been reported to be correlated with tumorigenesis. However, the roles of eRNAs in thyroid cancer (THCA) remain still unclear. This study aimed to construct an immune-related eRNA prognostic signature that could effectively predict the survival and prognosis for THCA.

METHODS

The Weighted Gene Co-Expression Network Analysis (WGCNA) was performed to identify THCA-specific immune-related hub genes and immune-related eRNAs were obtained using Pearson correlation analysis. Univariate and least absolute shrinkage and selection operator (LASSO) Cox regression were conducted to construct an immune-related eRNA prognostic signature in training cohort, and the predictive capability was verified in test cohort and entire cohort. Kaplan-Meier analysis, principal component analysis (PCA), receiver operating characteristic (ROC) curves, and nomogram were used to validate the risk signature. Furthermore, CIBERSORT, ESTIMATE and ssGSEA were analyzed to explore the tumor immune microenvironment (TIME) of the risk signature, and the response of potential immunotherapeutic were also discussed.

RESULTS

A total of 125 immune-related eRNAs were obtained and 16 immune-related eRNAs were significantly correlated with overall survival (OS). A 9-immune-related eRNA prognostic signature was constructed, and the risk score was identified as an independent predictor. High-risk groups were associated with a poorer OS. Immune microenvironment analysis indicated that low risk score was correlated with higher immuneScore, high immune cell infiltration, and the better response of immunotherapy. Additionally, we also detected 9 immune-related eRNA expression levels in sixty-two matched tumorous and non-tumorous tissues using qRT-PCR analysis.

CONCLUSION

Our immune-related eRNA risk signature that was an independent prognostic factor was strongly correlated with the immune microenvironment and may be promising for the clinical prediction of prognosis and immunotherapeutic responses in THCA patients.

摘要

背景

据报道,增强子RNA(eRNAs)的功能改变与肿瘤发生相关。然而,eRNAs在甲状腺癌(THCA)中的作用仍不清楚。本研究旨在构建一种免疫相关的eRNA预后特征,以有效预测THCA的生存和预后。

方法

进行加权基因共表达网络分析(WGCNA)以识别THCA特异性免疫相关枢纽基因,并使用Pearson相关分析获得免疫相关eRNAs。在训练队列中进行单因素和最小绝对收缩和选择算子(LASSO)Cox回归以构建免疫相关的eRNA预后特征,并在测试队列和整个队列中验证预测能力。使用Kaplan-Meier分析、主成分分析(PCA)、受试者工作特征(ROC)曲线和列线图来验证风险特征。此外,分析CIBERSORT、ESTIMATE和ssGSEA以探索风险特征的肿瘤免疫微环境(TIME),并讨论潜在免疫治疗的反应。

结果

共获得125个免疫相关eRNAs,其中16个免疫相关eRNAs与总生存期(OS)显著相关。构建了一个包含9个免疫相关eRNAs的预后特征,并将风险评分确定为独立预测因子。高风险组的OS较差。免疫微环境分析表明,低风险评分与较高的免疫评分、高免疫细胞浸润以及更好的免疫治疗反应相关。此外,我们还使用qRT-PCR分析检测了62对配对的肿瘤组织和非肿瘤组织中9个免疫相关eRNAs的表达水平。

结论

我们的免疫相关eRNA风险特征是一个独立的预后因素,与免疫微环境密切相关,可能对THCA患者的预后临床预测和免疫治疗反应具有重要意义。

相似文献

1
Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma.评估免疫相关的eRNA模型和特征分数,以预测甲状腺癌对免疫治疗的反应。
Cancer Cell Int. 2022 Oct 10;22(1):307. doi: 10.1186/s12935-022-02722-8.
2
Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma.肝细胞癌免疫相关eRNA预后标志物的鉴定与验证
Front Genet. 2021 Jun 11;12:657051. doi: 10.3389/fgene.2021.657051. eCollection 2021.
3
Identification and validation of a pyroptosis-related prognostic signature for thyroid cancer.甲状腺癌焦亡相关预后标志物的鉴定与验证
Cancer Cell Int. 2021 Oct 9;21(1):523. doi: 10.1186/s12935-021-02231-0.
4
Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma.构建用于预测甲状腺癌预后和免疫反应的铁死亡相关五lncRNA特征
Cancer Cell Int. 2022 Sep 29;22(1):296. doi: 10.1186/s12935-022-02674-z.
5
Comprehensive alteration-related transcriptomic characterization is involved in immune infiltration and correlated with prognosis and immunotherapy response of bladder cancer.全面的改变相关转录组学特征与膀胱癌的免疫浸润相关,并与预后和免疫治疗反应相关。
Front Immunol. 2022 Jul 26;13:931906. doi: 10.3389/fimmu.2022.931906. eCollection 2022.
6
Comprehensive transcriptomic analysis of immune-related eRNAs associated with prognosis and immune microenvironment in melanoma.黑色素瘤中与预后和免疫微环境相关的免疫相关eRNA的综合转录组学分析
Front Surg. 2022 Sep 9;9:917061. doi: 10.3389/fsurg.2022.917061. eCollection 2022.
7
Analysis of Prognostic Alternative Splicing Reveals the Landscape of Immune Microenvironment in Thyroid Cancer.预后性可变剪接分析揭示甲状腺癌免疫微环境格局
Front Oncol. 2021 Oct 18;11:763886. doi: 10.3389/fonc.2021.763886. eCollection 2021.
8
Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.免疫相关 eRNAs 驱动基因在肺腺癌中的预后和肿瘤免疫价值。
J Cancer Res Clin Oncol. 2024 Apr 11;150(4):188. doi: 10.1007/s00432-024-05687-5.
9
Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy.鉴定和验证甲状腺癌的新型衰老相关生物标志物,以预测预后和免疫治疗。
Front Immunol. 2023 Jan 24;14:1128390. doi: 10.3389/fimmu.2023.1128390. eCollection 2023.
10
An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma.一种炎症反应相关基因特征可影响免疫状态并预测肝细胞癌的预后。
Front Oncol. 2021 Mar 22;11:644416. doi: 10.3389/fonc.2021.644416. eCollection 2021.

引用本文的文献

1
Enhancer RNA in cancer: identification, expression, resources, relationship with immunity, drugs, and prognosis.癌症中的增强子RNA:鉴定、表达、资源、与免疫的关系、药物及预后
Brief Funct Genomics. 2025 Jan 15;24. doi: 10.1093/bfgp/elaf007.
2
Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis.21世纪放射性碘难治性甲状腺癌治疗的研究趋势与热点:一项文献计量分析
Ann Nucl Med. 2025 Jan;39(1):9-20. doi: 10.1007/s12149-024-01998-2. Epub 2024 Nov 5.
3
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer.

本文引用的文献

1
A Novel Prognostic Tool for Glioma Based on Enhancer RNA-Regulated Immune Genes.一种基于增强子RNA调控免疫基因的新型胶质瘤预后评估工具。
Front Cell Dev Biol. 2022 Jan 20;9:798445. doi: 10.3389/fcell.2021.798445. eCollection 2021.
2
Identification and Validation of Pyroptosis-Related Gene Signature to Predict Prognosis and Reveal Immune Infiltration in Hepatocellular Carcinoma.用于预测肝细胞癌预后并揭示免疫浸润的焦亡相关基因特征的鉴定与验证
Front Cell Dev Biol. 2021 Nov 8;9:748039. doi: 10.3389/fcell.2021.748039. eCollection 2021.
3
Enhancer RNA SLIT2 Inhibits Bone Metastasis of Breast Cancer Through Regulating P38 MAPK/c-Fos Signaling Pathway.
非小细胞肺癌患者新辅助PD-1阻断早期反应的血液分子和细胞生物标志物
Cancer Cell Int. 2024 Jun 29;24(1):225. doi: 10.1186/s12935-024-03412-3.
4
LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1.LINC00887 通过与 FOXQ1 结合作为增强子 RNA 促进甲状腺髓样癌的进展。
Curr Cancer Drug Targets. 2024;24(5):519-533. doi: 10.2174/0115680096258716231026063704.
5
Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review.从 1980 年到 2022 年甲状腺癌免疫治疗的知识图谱:综述。
Medicine (Baltimore). 2023 Sep 29;102(39):e35506. doi: 10.1097/MD.0000000000035506.
增强子RNA SLIT2通过调控P38 MAPK/c-Fos信号通路抑制乳腺癌骨转移
Front Oncol. 2021 Oct 15;11:743840. doi: 10.3389/fonc.2021.743840. eCollection 2021.
4
Identification and validation of a pyroptosis-related prognostic signature for thyroid cancer.甲状腺癌焦亡相关预后标志物的鉴定与验证
Cancer Cell Int. 2021 Oct 9;21(1):523. doi: 10.1186/s12935-021-02231-0.
5
A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma.一项前瞻性随机对照试验,旨在评估预防性中央区淋巴结清扫术在甲状腺乳头状癌中的疗效和安全性。
Surgery. 2022 Jan;171(1):182-189. doi: 10.1016/j.surg.2021.03.071. Epub 2021 Aug 12.
6
LncRNA AC007255.1, an immune-related prognostic enhancer RNA in esophageal cancer.长链非编码RNA AC007255.1,一种食管癌中与免疫相关的预后增强子RNA。
PeerJ. 2021 Jul 14;9:e11698. doi: 10.7717/peerj.11698. eCollection 2021.
7
Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.用于前列腺癌风险分层和预后的新型免疫相关特征
Cancer Sci. 2021 Oct;112(10):4365-4376. doi: 10.1111/cas.15062. Epub 2021 Aug 18.
8
A Novel Immune-Related Prognostic Signature in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中一种新型的免疫相关预后标志物
Front Genet. 2021 Jun 18;12:570336. doi: 10.3389/fgene.2021.570336. eCollection 2021.
9
Long Noncoding RNA WDFY3-AS2 Represses the Progression of Esophageal Cancer through miR-18a/PTEN Axis.长链非编码RNA WDFY3-AS2通过miR-18a/PTEN轴抑制食管癌进展。
J Oncol. 2021 Jun 5;2021:9951010. doi: 10.1155/2021/9951010. eCollection 2021.
10
Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma.肝细胞癌免疫相关eRNA预后标志物的鉴定与验证
Front Genet. 2021 Jun 11;12:657051. doi: 10.3389/fgene.2021.657051. eCollection 2021.